Clinical Research Directory

Inclusion Criteria: * Gender: female and/or male. * Age: adults and children from 6 years old: * The physician's score for at least two symptoms, in addition to a dry nose, must average at least 2 at the enrolment visit (Day 0), for a minimum total score of 6. * Subjects agree to refrain from taking any medication and/or taking any action to relieve nasal symptoms throughout the study, from Day -4 to Day 7, apart from acetaminophen. * Autonomous adult, or minor with the consent of their legal representative. * Subject and/or Parent/legal guardian of the subject has given freely and expressly her/his informed consent. * Subject and/or Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected. * Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use. * Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor. Exclusion Criteria: * Subjects taking anticoagulants, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), or topical or systemic decongestants within two weeks prior to Visit 1 and during the study. * Subjects using other nasal sprays, nasal pumps, nasal irrigation/rinsing devices, or oils, creams, or gels in the nose within two weeks prior to Visit 1 and during the study. * Subjects with a history of sensitivity to products related to the product being evaluated. * Subjects with any clinically significant comorbid condition that, in the opinion of the principal investigator, could affect the subject's safety and/or participation in the study. * Person whose ability to use the product daily and complete the daily follow-up diary is in doubt. * Person refusing to sign the informed consent form prior to the study. * Person participating or having participated in any other clinical study within the 30 days preceding the study. * Person participating in any other clinical study.